Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Biotechnology

Purple Biotech Ltd ADR

PPBT · NASDAQ · USD · Market cap $1M · 10 employees

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.

FAIL · Does not pass the screen
1.71 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price1.71 USD at the 17 Nov 2026 close
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-17).

Current read
Markup ?
Screened · screened 2026-11-17
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price1.71 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-11Read Markup1.34+27.6% to today ✓Distribution gives way to Markup after a 15% rise in 9 days
2026-11-02Read Distribution1.17+46.2% to today Markdown gives way to Distribution after a 19% slide in 3 weeks
2026-10-11Read Markdown1.44+18.8% to today Distribution gives way to Markdown
2026-10-02Read Distribution1.44+18.8% to today Markup gives way to Distribution first Distribution read since August

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Purple Biotech Ltd ADR holds its Markup at $1.71. The statistical read favours the sellers, held for 60 days.

As held on the ledger · 2026-11-17
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 60 days
Price at the screen$1.71
Valuation0.00 trailing · -1.67 forward price to earnings
Values screenFAIL · score 70.0
Beta-0.55
The Workings

Five Screens, Shown in Full

Does not pass. Accounts receivable

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 1.39% Below 33% Interest-bearing debt is just 1.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 4.88% Below 33% Cash held in interest-bearing accounts and securities is 4.9% of assets, under the one-third limit. Pass
Receivables 50.49% Below 49% Money owed to the company is 50.5% of assets, above the 49% limit. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Purple Biotech's business is fine, but its receivables are about 50% of its assets, just over the ~49% line, so it does not pass on the financial screens.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when PPBT's ethical verdict changes

Today PPBT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

How a fair value is estimated: discounted cash flow (DCF).

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-1.7x
Trailing P/E0.0x
EPS, trailing3,226.00
EPS, forward-0.88
Profit margin0.0%currently unprofitable
Return on equity-123.3%not currently earning a positive return on equity
FCF yield-182.14%
Debt to equity1.90a meaningful debt load worth watching
Current ratio1.48adequate liquidity, worth monitoring
Beta-0.55barely tracks the market's swings
Short interest, float0.03%
52-week range1.35 - 29.00
MoatNONE
Market cap$1M
Employees10

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

PPBT trades on NASDAQ (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-11 Markup · changed $1.34 +14.5% Entry 10

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-11-02 Distribution · changed $1.17 -4.9% Entry 9

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-10-26 Markdown $1.23 -14.6% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-10-11 Markdown · changed $1.44 +0.0% Entry 7

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-10-02 Distribution · changed $1.44 -2.0% Entry 6

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-09-09 Markup · changed $1.47 +0.0% Entry 5

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-08-09 Distribution $1.47 -7.0% Entry 4

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-07-18 Distribution $1.58 +0.0% Entry 3

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 89%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (1 analysts) rates it none, with a mean price target of $30.

2026-07-03 Distribution $1.58 +0.0% Entry 2

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Distribution $1.58 Entry 1

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in PPBT's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $4.06 -29.8% · $702 -29.8%
2 months $4.13 -31.0% · $690 -31.0%
3 months $3.84 -25.8% · $742 -25.8%
6 months $8.22 -65.3% · $347 -65.3%
1 year $26.94 -89.4% · $106 -89.4%
2 years $110.00 -97.4% · $26 -97.4%
3 years $320.00 -99.1% · $9 -99.1%
5 years $1,006.00 -99.7% · $3 -99.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever PPBT does next, these words stay.

Purple Biotech Ltd ADR · PPBT · Markup · $1.71
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.